Physician profile
Mary E Templin
NPI 1760798961
$19,065.05
in general payments reported to CMS, 2019-2025
36 companies · $3,202 in 2025
The $3,202 reported for 2025 was more than what 97% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,521 · 2022: $3,959 · 2023: $4,304 · 2024: $5,079 · 2025: $3,202.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $12K · Consulting Fee: $718 · Education: $271.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,596.61 |
| Consulting Fee | $717.50 |
| Education | $270.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,370.92 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $1,718.84 | 2021-2025 | |
| Leo Pharma INC. | $1,382.77 | 2021-2025 | Adbry, Anzupgo |
| Sun Pharmaceutical Industries INC. | $1,379.43 | 2021-2025 | Winlevi, Absorica Ld, Ilumya |
| Regeneron Healthcare Solutions, INC. | $1,247.33 | 2021-2025 | Dupixent, Libtayo |
| Lilly USA, LLC | $1,145.25 | 2021-2025 | Taltz, Ebglyss |
| Incyte Corporation | $996.97 | 2021-2025 | Opzelura, Opzelura |
| Mayne Pharma Commercial LLC | $958.59 | 2021-2025 | |
| Epi Health, LLC | $953.61 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $796.26 | 2022-2024 | Sotyktu |
| Arcutis Biotherapeutics, INC. | $769.36 | 2023-2025 | Zoryve |
| Pfizer INC. | $618.60 | 2021-2025 | |
| Dermavant Sciences, INC. | $604.12 | 2022-2024 | Vtama |
| Genzyme Corporation | $579.47 | 2021-2024 | |
| Janssen Biotech, INC. | $529.56 | 2021-2025 | Tremfya |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $506.41 | 2021-2025 | Bimzelx, Cimzia |
| Galderma Laboratories, L.P. | $443.82 | 2021-2025 | Nemluvio, Aklief, Oracea |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $442.47 | 2021-2025 | Arazlo, Jublia, Cabtreo |
| Allergan, INC. | $402.94 | 2021-2022 | |
| Vyne Pharmaceuticals INC. | $245.29 | 2021 | |
| Journey Medical Corporation | $218.16 | 2023-2025 | |
| Organon LLC | $208.83 | 2024-2025 | Vtama, Hadlima |
| Amgen INC. | $130.06 | 2022-2025 | Otezla, Otezla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $77.00 | 2023-2025 | Spevigo |
| Biofrontera INC. | $56.49 | 2022-2025 | Ameluz |
| Verrica Pharmaceuticals INC. | $38.08 | 2023-2024 | Ycanth |
| Almirall LLC | $35.56 | 2021-2023 | Klisyri |
| Botanix Sb INC | $35.50 | 2025 | Sofdra |
| Kerecis Limited | $35.03 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Organogenesis INC. | $31.95 | 2025 | Affinity |
| Sanofi-Aventis U.S. LLC | $24.52 | 2021 | |
| Revance Therapeutics, INC. | $20.61 | 2024 | Daxxify |
| Convatec INC. | $18.36 | 2025 | |
| Genentech USA, INC. | $15.96 | 2022 | |
| Helsinn Therapeutics (U.S.), INC. | $13.50 | 2021 | |
| Nabriva Therapeutics, Plc | $13.43 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Templin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.